Compare MVBF & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MVBF | CUVL |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Miscellaneous |
| Sector | Finance | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.2M | 374.2M |
| IPO Year | 2004 | 2004 |
| Metric | MVBF | CUVL |
|---|---|---|
| Price | $23.01 | $4.92 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $30.50 | N/A |
| AVG Volume (30 Days) | ★ 65.8K | 5.6K |
| Earning Date | 10-29-2026 | 08-27-2026 |
| Dividend Yield | ★ 2.91% | 0.60% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $3,400,000.00 | N/A |
| Revenue This Year | N/A | $0.47 |
| Revenue Next Year | $10.88 | $6.25 |
| P/E Ratio | $17.30 | ★ N/A |
| Revenue Growth | ★ 51.92 | N/A |
| 52 Week Low | $23.01 | $4.79 |
| 52 Week High | $31.99 | $8.20 |
| Indicator | MVBF | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 21.24 | 30.91 |
| Support Level | N/A | N/A |
| Resistance Level | $26.60 | $5.34 |
| Average True Range (ATR) | 0.88 | 0.16 |
| MACD | -0.20 | -0.01 |
| Stochastic Oscillator | 3.26 | 16.67 |
MVB Financial Corp is a financial holding company. The company provides a wide range of business activities through the Bank, commercial and retail banking services, as well as Fintech banking. It has three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of its revenue is generated from the CoRe Banking segment, which includes its Fintech division, represents banking products and services offered to customers by the Bank, loans and deposits accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.